BridgeBio Pharma Inc
BBIO
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
195.8% downsideOvervalued by 195.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.69 Billion |
|---|---|
| Enterprise Value | $14.86 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.79 |
| Beta | 0.95 |
| Outstanding Shares | 194,789,897 |
Return
| Return on Equity | 32.00% |
|---|---|
| Return on Assets | -52.95% |
| Return on Invested Capital | -109.98% |
Valuation & Multiples
| P/E Ratio | -21.36 |
|---|---|
| PEG | 1058.21 |
| Price to Sales | 40.05 |
| Price to Book Ratio | -6.67 |
| Enterprise Value to Revenue | 26.25 |
| Enterprise Value to EBIT | -24.36 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4458▲ 29.54% |
|---|---|
| Total Calls | 134,600▼ 98.70% |
| Total Puts | 60,000▼ 96.15% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.56%▼ 98.37% |
|---|---|
| Total Invested | $411.19M▼ 97.15% |
| Investors Holding | 112▼ 379.00% |
ESG Score
No data
About BridgeBio Pharma Inc
CEO: Neil Kumar Relevant Senate Committees
This non-partisan committee provides critical analysis and official 'revenue estimates' for all tax legislation, directly influencing corporate tax structures and the overall financial burden on pharmaceutical companies.
This committee controls taxation, trade, and entitlement spending, directly impacting corporate valuations through tax policy and significantly influencing revenue streams through Medicare pricing and reimbursement policies for pharmaceuticals.
This committee directly regulates the FDA (primary regulator for drug approval) and influences NIH funding for research, making it highly impactful on a pharmaceutical company's product development and market access.
This committee oversees antitrust laws and intellectual property (patents), both of which are absolutely critical to the business model, mergers, and competitive landscape of pharmaceutical companies.